Université de Montreal has identified new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer, inflammatory and immunological disorder.

Hangzhou Institute of Medicine Chinese Academy of Sciences has patented new nitrogen-containing heteroaryl compounds acting as CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.

A recent Antelope Therapeutics SAS patent describes new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting canAg (CA242) mucin glycoepitope covalently linked to exatecan designed for use in the treatment of cancer.